653 related articles for article (PubMed ID: 35001525)
1. Idiopathic pulmonary fibrosis: Current and future treatment.
Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; DeLeon J; Reiss AB
Clin Respir J; 2022 Feb; 16(2):84-96. PubMed ID: 35001525
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches.
Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; Kasselman LJ; Glass AD; DeLeon J; Reiss AB
Respir Investig; 2020 Sep; 58(5):320-335. PubMed ID: 32487481
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Maher TM; Strek ME
Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
[TBL] [Abstract][Full Text] [Related]
5. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK
Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies.
Selvarajah B; Platé M; Chambers RC
Mol Aspects Med; 2023 Dec; 94():101227. PubMed ID: 38000335
[TBL] [Abstract][Full Text] [Related]
8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
9. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis.
Koudstaal T; Wijsenbeek MS
Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
[TBL] [Abstract][Full Text] [Related]
14. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
16. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Moodley Y; Corte T; Richeldi L; King TE
Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols.
Patel H; Shah JR; Patel DR; Avanthika C; Jhaveri S; Gor K
Dis Mon; 2023 Jul; 69(7):101484. PubMed ID: 36220705
[TBL] [Abstract][Full Text] [Related]
18. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
20. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
Ebrahimpour A; Ahir M; Wang M; Jegga AG; Bonnen MD; Eissa NT; Montesi SB; Raghu G; Ghebre YT
Sci Rep; 2022 Nov; 12(1):20668. PubMed ID: 36450789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
